Long-term follow-up study of patients who have previously been exposed to UCART19

Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor) - LTFU study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2013190001

Enrollment

200

Registered

2019-04-28

Start date

2020-03-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced lymphoid malignancies

Interventions

UCART19 administration in parent studies

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients dosed with UCART19 must be enrolled in the long-term follow up study after the completion of the parent study.

Exclusion criteria

Exclusion criteria: No exclusion criteria for this study.

Design outcomes

Primary

Measure	Time frame
To evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19	—

Secondary

Measure	Time frame
To assess the long term anti leukemic activity of UCART19 etc	—

Countries

Belgium, France, Japan, UK, USA

Contacts

Public ContactInternational center for therapeutic research clinical operation department

Nihon Servier Company Limited

clinicaltrials.jpn@servier.com+81-3-4520-2350

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026